Education
About Us
Working with TipRanks
Follow Us
RSPH - ETF AI Analysis
Top Page
Invesco S&P 500 Equal Weight Health Care ETF (RSPH)
Rating:71Outperform
Price Target:―
Positive Factors
Broad Mix of Health Care Stocks
The ETF holds many different health care companies, so it is not overly dependent on any single stock.
Several Strong-Performing Holdings
Some of the top positions, such as Moderna and other key names, have shown strong gains this year, helping support overall returns.
Solid Asset Base
The fund manages a sizable pool of assets, which can help with trading liquidity and overall fund stability for investors.
Negative Factors
Single-Sector Concentration
Almost all of the ETF’s assets are in the health care sector, so its performance is highly tied to how this one industry does.
U.S.-Only Exposure
The fund invests almost entirely in U.S. companies, offering little geographic diversification if the U.S. market struggles.
Moderate Expense Ratio
The ETF’s fee is not especially low, which slightly reduces the net return investors keep over time.
RSPH vs. SPDR S&P 500 ETF (SPY)
AUM761.83M
RegionNorth America
Expense Ratio0.40%
Beta0.58
IssuerInvesco
Inception DateNov 01, 2006
Dividend Yield0.69%
Asset ClassEquity
Index TrackedS&P 500 Equal Weighted / Health Care -SEC
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume93,288
30 Day Avg. Volume87,971
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
36.65Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering61
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RSPH Summary
RSPH is the Invesco S&P 500 Equal Weight Health Care ETF. It tracks a version of the S&P 500 health care index where each company gets roughly the same weight, instead of letting the biggest companies dominate. It holds a wide mix of U.S. health care businesses, including drug makers, biotech firms, medical device companies, and insurers. Well-known names include Moderna and Merck. Someone might invest for focused exposure to the long-term growth and innovation in health care, while still being diversified within the sector. A key risk is that it is heavily concentrated in health care, so it can rise or fall with that sector.
How much will it cost me?The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) has an expense ratio of 0.40%, which means you’ll pay $4 per year for every $1,000 invested. This is slightly higher than average for ETFs because it uses an equal-weight strategy, which requires more active management compared to passively managed funds that track a standard index.
What would affect this ETF?The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) could benefit from advancements in medical technology, increased demand for health care services due to aging populations, and innovation in biotechnology and pharmaceuticals. However, it may face challenges from regulatory changes, pricing pressures in the health care industry, and potential economic downturns that could reduce consumer spending on health care. Its U.S. focus and equal-weight strategy provide diversification but may limit exposure to faster-growing international markets.
RSPH Top 10 Holdings
RSPH is a pure U.S. health care play, and its story right now is all about stock pick balance rather than one giant name calling the shots. Moderna has been a key engine, rising on renewed optimism around its pipeline, while Bio-Techne and Revvity are also pulling their weight with steady to strong momentum despite valuation worries. On the steadier side, Merck and Thermo Fisher act like the fund’s defensive backbone, contributing more quietly. Managed-care names like Molina and Centene are more mixed, occasionally losing steam and keeping overall gains from running too hot.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Moderna | 2.49% | $18.87M | $17.22B | 11.80% | 59 Neutral | |
| Gilead Sciences | 1.92% | $14.54M | $176.11B | 46.04% | 78 Outperform | |
| Merck & Company | 1.85% | $14.04M | $273.69B | 11.59% | 80 Outperform | |
| Viatris | 1.85% | $14.03M | $15.08B | 16.05% | 60 Neutral | |
| Centene | 1.83% | $13.92M | $21.29B | -32.34% | 58 Neutral | |
| Molina Healthcare | 1.83% | $13.91M | $9.23B | -42.14% | 71 Outperform | |
| Johnson & Johnson | 1.80% | $13.68M | $547.51B | 49.36% | 78 Outperform | |
| Baxter International | 1.80% | $13.66M | $10.32B | -38.36% | 45 Neutral | |
| Cardinal Health | 1.78% | $13.47M | $51.05B | 73.77% | 66 Neutral | |
| Amgen | 1.78% | $13.47M | $184.10B | 19.78% | 77 Outperform |
RSPH Technical Analysis
Positive
―
Price Trends
32.18
Positive
31.05
Positive
29.82
Positive
Market Momentum
0.10
Positive
45.12
Neutral
12.80
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RSPH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 32.80, equal to the 50-day MA of 32.18, and equal to the 200-day MA of 29.82, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 45.12 is Neutral, neither overbought nor oversold. The STOCH value of 12.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RSPH.
RSPH Peer Comparison
Comparison Results
Performance Comparison
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
32.25
1.23
3.97%
IHE
iShares U.S. Pharmaceuticals ETF
―
―
―
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
PINK
Simplify Health Care ETF
―
―
―
PSCH
Invesco S&P SmallCap Health Care ETF
―
―
―
PTH
Invesco DWA Healthcare Momentum ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents